Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions

SRA-NED JPND Working Group

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction: Molecular, functional, and structural neuroimaging biomarkers are largely used to study neurodegenerative diseases, but their benefits to patients/science might be greatly enhanced by improving standardization and cross-validation. In this EU Joint Programme-Neurodegenerative Diseases Research–funded project, we surveyed the neuroimaging community to assess perceived barriers in multicentric neuroimaging harmonization and actions to overcome them. Methods: An anonymous survey addressed researchers, clinicians, pharma industry, and professional associations, inquiring about both general and modality-specific harmonization barriers. Results: Survey participants (459) represented an international (37 countries) multidisciplinary community. We identified two sets of funding actions, one proposing the creation of an updated hub of documents to help researchers plan and execute multicentric neuroimaging studies capitalizing from previous studies, and the other focused on modality-specific harmonization challenges in future neurodegenerative diseases clinical trials. Discussion: This large survey of priorities and actions may help define harmonization calls launched by worldwide science funding agencies.
Original languageEnglish
Pages (from-to)69-73
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume11
DOIs
Publication statusPublished - 2019

Cite this

@article{15a7d2936a9b49e08691d348e00448ac,
title = "Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions",
abstract = "Introduction: Molecular, functional, and structural neuroimaging biomarkers are largely used to study neurodegenerative diseases, but their benefits to patients/science might be greatly enhanced by improving standardization and cross-validation. In this EU Joint Programme-Neurodegenerative Diseases Research–funded project, we surveyed the neuroimaging community to assess perceived barriers in multicentric neuroimaging harmonization and actions to overcome them. Methods: An anonymous survey addressed researchers, clinicians, pharma industry, and professional associations, inquiring about both general and modality-specific harmonization barriers. Results: Survey participants (459) represented an international (37 countries) multidisciplinary community. We identified two sets of funding actions, one proposing the creation of an updated hub of documents to help researchers plan and execute multicentric neuroimaging studies capitalizing from previous studies, and the other focused on modality-specific harmonization challenges in future neurodegenerative diseases clinical trials. Discussion: This large survey of priorities and actions may help define harmonization calls launched by worldwide science funding agencies.",
author = "{SRA-NED JPND Working Group} and Jorge Jovicich and Frederik Barkhof and Claudio Babiloni and Karl Herholz and Christoph Mulert and {van Berckel}, {Bart N. M.} and Frisoni, {Giovanni B.}",
year = "2019",
doi = "10.1016/j.dadm.2018.11.005",
language = "English",
volume = "11",
pages = "69--73",
journal = "Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions

AU - SRA-NED JPND Working Group

AU - Jovicich, Jorge

AU - Barkhof, Frederik

AU - Babiloni, Claudio

AU - Herholz, Karl

AU - Mulert, Christoph

AU - van Berckel, Bart N. M.

AU - Frisoni, Giovanni B.

PY - 2019

Y1 - 2019

N2 - Introduction: Molecular, functional, and structural neuroimaging biomarkers are largely used to study neurodegenerative diseases, but their benefits to patients/science might be greatly enhanced by improving standardization and cross-validation. In this EU Joint Programme-Neurodegenerative Diseases Research–funded project, we surveyed the neuroimaging community to assess perceived barriers in multicentric neuroimaging harmonization and actions to overcome them. Methods: An anonymous survey addressed researchers, clinicians, pharma industry, and professional associations, inquiring about both general and modality-specific harmonization barriers. Results: Survey participants (459) represented an international (37 countries) multidisciplinary community. We identified two sets of funding actions, one proposing the creation of an updated hub of documents to help researchers plan and execute multicentric neuroimaging studies capitalizing from previous studies, and the other focused on modality-specific harmonization challenges in future neurodegenerative diseases clinical trials. Discussion: This large survey of priorities and actions may help define harmonization calls launched by worldwide science funding agencies.

AB - Introduction: Molecular, functional, and structural neuroimaging biomarkers are largely used to study neurodegenerative diseases, but their benefits to patients/science might be greatly enhanced by improving standardization and cross-validation. In this EU Joint Programme-Neurodegenerative Diseases Research–funded project, we surveyed the neuroimaging community to assess perceived barriers in multicentric neuroimaging harmonization and actions to overcome them. Methods: An anonymous survey addressed researchers, clinicians, pharma industry, and professional associations, inquiring about both general and modality-specific harmonization barriers. Results: Survey participants (459) represented an international (37 countries) multidisciplinary community. We identified two sets of funding actions, one proposing the creation of an updated hub of documents to help researchers plan and execute multicentric neuroimaging studies capitalizing from previous studies, and the other focused on modality-specific harmonization challenges in future neurodegenerative diseases clinical trials. Discussion: This large survey of priorities and actions may help define harmonization calls launched by worldwide science funding agencies.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85059693369&origin=inward

U2 - 10.1016/j.dadm.2018.11.005

DO - 10.1016/j.dadm.2018.11.005

M3 - Article

VL - 11

SP - 69

EP - 73

JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

SN - 2352-8729

ER -